GLP-1 therapy, insulin resistance and metabolic optimisation. Doctor-led assessment — not just a prescription.
Book a consultation →Obesity and metabolic dysfunction are complex medical conditions — not a failure of willpower. GLP-1 receptor agonists (semaglutide/Wegovy and tirzepatide/Mounjaro) represent a significant advance in treatment, but they are most effective when prescribed as part of a proper medical programme that includes assessment, monitoring and lifestyle support.
Dr Qurbain’s approach addresses the underlying metabolic picture: insulin resistance, inflammation, hormonal factors and lifestyle — alongside medication where appropriate. The goal is sustainable health improvement, not a quick fix.
Semaglutide (Wegovy) and tirzepatide (Mounjaro) are NICE-approved treatments for obesity. Dr Qurbain assesses eligibility, initiates treatment at the appropriate starting dose and oversees titration and monitoring. Prescribing follows NICE TA875 and TA924.
Many people carry significant metabolic risk for years before diagnosis. Dr Qurbain reviews HbA1c, fasting glucose, insulin levels and lipids — and offers evidence-based interventions to reduce progression to type 2 diabetes.
Central obesity, raised blood pressure, dyslipidaemia and insulin resistance frequently cluster together. A comprehensive metabolic assessment identifies the full picture and enables a targeted treatment plan.
Medication alone rarely produces lasting change. Dr Qurbain provides evidence-based dietary and lifestyle guidance aligned with current NICE recommendations, tailored to your preferences and lifestyle.
45-minute video consultation · Full metabolic blood panel review · Personalised programme · GLP-1 prescription where appropriate
Book now →Doctor-led. Evidence-based. No shortcuts.
Book a consultation →Or email hello@metovia.co.uk